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The aim of the study was to prospectively evaluate an intensive follow-up programme using serial tumour marker estimations and
contrast-enhanced computed tomography (CT) of the chest and abdomen in patients undergoing potentially curative resection of
colorectal liver metastases. Seventy-six consecutive patients having undergone potentially curative resections of colorectal liver
metastases in a single unit were followed up with a protocol of 3 monthly carcinoembryonic antigen and carbohydrate antigen 19-9
estimations and contrast-enhanced spiral CT of the chest, abdomen and pelvis for the first 2 years following surgery and 6 monthly
thereafter. The median period of follow-up was 24 months (range 18–60). Recurrent tumour was classed as early if within 6 months
of liver resection. Thirty-seven of the 76 patients (49%) developed recurrence on follow-up. Nineteen recurrences were in the liver
alone (51%), 16 liver and extrahepatic (43%) and two extrahepatic alone (6%). Of the 19 patients with isolated liver recurrence, eight
developed within 6 months of liver resection none of which were resectable. Of the 11 recurrences after 6 months, five (45%) were
resectable. Of the 37 recurrences, CT indicated recurrence despite normal tumour markers in 19 patients. Tumour markers
suggested recurrence before imaging in 12 and concurrently with imaging in 6. In the 12 patients who presented with elevated
tumour markers before imaging, there was a median lag period of 3 months (range 1–21) in recurrence being detected on further
serial imaging. Seventeen patients who developed recurrence had normal tumour markers before initial resection of their liver
metastases. Of these 17, 10 (58%) had an elevation of tumour markers associated with recurrence. Over a median follow-up of 2
years following liver resection, the use of CT or tumour markers alone would have failed to demonstrate early recurrence in 12 and
18 patients respectively. A combination of tumour markers and CT detected significantly more (Po0.05) recurrence than either
modality alone. Tumour markers and CT should be used in combination in the follow-up of patients with resected colorectal liver
metatases, including patients whose markers are normal at the time of initial liver resection.
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The incidence of colorectal cancer in the Western World is
approximately 50 per 100000 with a cumulative lifetime risk of
approximately 5% (Rudy and Zdon, 2000; Malafosse et al, 2001;
McCormick et al, 2002). Liver metastases are one of the principal
causes of death in these patients. About 25% of patients have liver
metastases at the time of presentation and another 20% subse-
quently develop liver metastases (Norum et al, 1997; Lyass et al,
2001). Median survival of untreated colorectal liver metastases is
approximately 9 months with few survivors beyond 2 years
(Bengtsson et al, 1981; Fujimoto et al, 1985; Giacchi et al, 1988;
Daly et al, 1989). The reported 5-year survival following surgical
resection of liver metastases is between 35 and 40% (Scheele et al,
1990; Ballantyne and Quin, 1993; Leow et al, 1997; Beard et al,
2000; Bolton and Fuhrman, 2000; Ruiz et al, 2000; Weber et al,
2000; Yamaguchi et al, 2000; Ruers and Bleichrodt, 2002).
A variety of imaging strategies have been suggested in the
follow-up of patients after resection of colorectal liver metastases
(Tartter et al, 1981; Fantini and DeCosse, 1990; Baulieu et al, 2001;
Glover et al, 2002; Longo and Johnson, 2002). The presence of
recurrent liver metastases was historically considered to have a
poor prognosis and routine screening for patients having under-
gone resection of colorectal liver metastases was felt not to be
justified by analysis of cost to benefit ratio (Biggs and Ballantyne,
1994; Beard et al, 2000). However, recent studies have shown a 35–
40% survival at 5 years following surgery for recurrent liver
metastases (Tuttle et al, 1997; Yamamoto et al, 1999a; Muratore
et al, 2001; Suzuki et al, 2001; Yamada et al, 2001a). These results
reflect a better outcome with a more aggressive approach towards
the treatment of colorectal liver metastases and careful follow-up Received 3 February 2006; revised 20 April 2006; accepted 15 May 2006
*Correspondence: Professor BR Davidson;
E-mail: b.davidson@medsch.ucl.ac.uk
British Journal of Cancer (2006) 95, 21–26
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sof patients following resection of the liver metastases is therefore
essential.
The main follow-up options for patients with resected colorectal
liver metastases combine serial estimations of tumour markers
with imaging by ultrasound, computed tomography (CT),
magnetic resonance imaging or position emission tomography
(PET) scan. Spiral CT has a high accuracy in the detection of
colorectal liver metastases (Bhattacharjya et al, 2004). This
prospective study presents the results of using serial tumour
marker estimation in conjunction with contrast-enhanced CT of
the chest, abdomen and pelvis in the follow-up of patients
following liver resection for colorectal metastases.
MATERIALS AND METHODS
Prospectively collected data on 76 patients who had undergone
potentially curative resection for colorectal liver metastases in a
single centre over a 5-year period from January 1996 to December
2001 was reviewed. During this period 120 patients were referred
for consideration of liver surgery for metastases following a
curative resection of a colorectal cancer. Staging investigations
over this time period included contrast CT of the chest, abdomen
and pelvis, a dynamic gadolinium enhanced magnetic resonance of
the liver and a CT arterial portography. At surgery these patients
were further assessed with intra-operative ultrasound and
bimanual palpation. The results of this staging algorithm have
been previously described (Bhattacharjya et al, 2004).
Eighty-nine patients had resection of their liver metastases. Of
these 13 were excluded from the current follow-up study owing to
noncurative liver resections (margin positive n¼4) or incomplete
follow-up (n¼9). All 76 patients had tumour marker estimation
before liver resection and at 6 weeks following surgery. The
patients entered a follow-up protocol of measuring serum
carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9
(CA 19-9) plus contrast-enhanced spiral CT (CECT) of the chest
and abdomen at 3 monthly intervals for the first 2 years and
thereafter at 6 monthly intervals till 5 years. The imaging protocol
for the contrast CT of the chest and abdomen during follow-up was
the same as used for pre-operative staging and is outlined below.
The follow-up imaging was carried out at the Royal Free Hospital.
The minimum period of follow-up was 18 months, median 24
months.
Technique of CECT of the chest
Contrast-enhanced axial images of the chest were obtained on a GE
HiSpeed spiral CT with 10mm collimation at 10–15ms
 1 table
speed 20s following injection of 75–100ml Omnipaque 300
(Nycomed, Amersham Health, Little Chalfont, Bucks, UK) through
a peripheral vein. Well-defined nonenhancing lesions of soft tissue
density in the lung parenchyma were considered to be suspicious
and were followed up by either fluoro-2-deoxy-D-glucose (FDG)
PET scan or repeat CECT of the chest at 6 weeks. Lesions that
showed uptake of FDG or had increased in size were classified as
pulmonary metastases.
Technique of CECT of the abdomen
Portal phase images were obtained 70s following injection of 75–
100ml Omnipaque 300 through a peripheral vein infused at a rate
of 4ml/s
 1 on a GE HiSpeed spiral CT with 7–10mm collimation
at 10–15mms
 1 table speed. The abdominal scans were
performed from the level of the domes of the diaphragm to the
symphysis pubis. Continguous 7- to-10-mm-thick axial images
were reconstructed from the volumetric data. Well-defined non-
enhancing water density lesions were considered to be benign. Iso-
or hypodense lesions with rim enhancement were considered to
represent metastases. Consultant radiologists with an interest in
hepatobiliary radiology reviewed the images. An ordinal category
system was used to group the patients with liver metastases into
solitary metastases H1, 2–5 metastases H2 and 45 metastases H3.
Carcinoembryonic antigen and CA19-9 levels were assessed in
the serum by immunoassay techniques performed on the Roche
Analyser E170 (Roche Diagnostics, Lewes, East Sussex UK). Serum
CEA levels greater than 5ngml
 1 and CA 19-9 levels greater than
37Uml
 1 were considered abnormal. Tumour marker levels were
correlated with findings on imaging and clinical follow-up of the
patients. The effect of the following variables on disease-free
survival was assessed: Duke’s stage of bowel cancer, tumour
marker levels, number of liver metastases and adjuvant chemo-
therapy for the primary colon cancer.
A cost analysis of the protocol based on costs for private
investigations in an NHS hospital was performed. The cost of the
follow-up surveillance programme was evaluated based on an
estimated cost of a spiral CT at d500.00 and cost per CEA and
CA19-9 estimation at d5.00 per test. The cost of clinician follow-up
time was not analysed.
Statistical analysis was performed using SPSS version 10.
Survival was assessed using Kaplan–Meier curves and compared
by the log-rank test. w
2 and where appropriate Fishers exact test
were used. Statistical significance was considered to be present on
Po0.05.
RESULTS
Seventy-six consecutive patients who had undergone liver resec-
tion for colorectal liver metastases were analysed in this follow-up
study. The median age was 60 years (range 29–77) with a male-to-
female ratio of 40:36. Fifty of the 76 patients presented with
synchronous metastases, whereas 26 had metachronous meta-
stases. Forty-two had a node negative and 34 a node-positive
primary tumour. All primary resections had clear histological
resection margins. Thirty patients had a solitary metastasis, 44 had
2–5 and 245 metastases (Table 1). Nineteen patients underwent a
right or left hepatectomy, 13 an extended right or left hepatectomy
and 38 a segmental (n¼20) or nonanatomical wedge hepatic
resection (n¼18). Five patients had an extended hepatectomy plus
wedge resection (Table 2).
Results of CT scans were available for all 76 patients and there
were a total of eight scans per patient during the median 24 month
follow-up (range of follow-up 18–60 months). Fifty-four patients
Table 1 Profile of patients undergoing liver resection for colorectal metastases
Dukes’ stage of primary Number of patients Sex M:F Syn. Met. Mean CEA (ngml
 1) Mean Ca 19-9 (Uml
 1)H 1 : H 2 : H 3
A 1 1:0 0 1 5 13 0:1:0
B 41 23:18 22 19 254 666 19:21:1
C 34 16:18 28 6 176 158 11:22:1
Syn., synchronous colorectal liver metastases; Met., Metachronous colorectal liver metastases; mean CEA, at time of initial liver resection (normal levels 1–5ngml
 1); mean CA
19-9, At the time of initial liver resection (normal levels 17–37Uml
 1); H1, solitary metastasis; H2, 2–5 liver metastases; H3, 45 liver metastases.
Intensive follow-up after liver resection
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swere followed up at our centre exclusively and eight results for
tumour marker estimations were available for each of these
patients during the follow-up period. Twenty-two patients were
followed up jointly with their referring hospitals. In these 22
patients, the tumour marker estimation was performed locally and
a median of 6 (range 4–8) results was available for this group.
No recurrence was detected in 39 patients over the follow-up
period. Thirty-seven patients had a recurrence. Fifteen presented
with recurrence within 6 months of the liver resection and 22 more
than 6 months following liver resection (Table 3). Nineteen had
recurrence in the liver only, 13 liver and lungs, three liver and hilar
and celiac lymph nodes and two had extrahepatic recurrence
(Table 3). Recurrence following liver resection was not influenced
by the Dukes stage of the primary bowel cancer, 20 of the 41
patients with a Dukes B cancer developed recurrence (49%) and 17
of the 34 with a Dukes C stage cancer (50%). Of the 20 recurrences
who had Dukes B cancers, six recurred within and 14 after 6
months of liver resection. Of the 17 Dukes C recurrences nine
recurred within 6 months and eight after 6 months. Delayed
recurrence was more common in the Dukes’ B group (14 out of 20,
70%) than the Dukes’ C group (eight out of 17, 47%), although this
was not statistically significant.
Of the patients with recurrent metastases, 15 underwent initial
resection for solitary liver metastases (H1), 21 2–5 metastases (H2)
and 145 metastases (H3). Nine patients had a right or left
hepatectomy, seven an extended hepatectomy, 18 had a wedge
resection and three an extended hepatectomy plus wedge resection
for their liver metastases at initial presentation (Table 4). No
association was observed in the type of resection performed or
number of tumours (H stage) and the timing of recurrence being
detected.
Of the 76 patients included in this study, 65 had raised (secreting
tumours) and 17 had normal (nonsecreting tumours) tumour
markers before the first liver resection. In the 37 patients with
recurrences, 12 (group 1) had raised tumour markers before CT
evidence; six (group 2) had tumour markers correlating with CT
evidence and 19 patients (group 3) had CT evidence of recurrence
before elevation of tumour markers. In group 1, five patients had
elevated tumour markers at the time of initial liver resection and
had therefore, secreting tumours. In groups 2 and 3, three and 12
patients had secreting tumours respectively (Table 5). In total, 20
of the 37 patients with recurrences had secreting tumours and in
them elevated tumour markers were predictive of recurrence in
eight (40%). Seventeen patients did not have a secreting tumour
and in 10 (59%) elevated tumour markers on follow-up were
predictive of recurrence. Raised tumour markers were the first
indication of recurrent disease in 18 of 76 patients (24%). Normal
tumour marker levels with CT evidence of recurrence were noted
in 19 of 76 patients (25%). A protocol of using both tumour
markers and CT in the postoperative period significantly improved
the diagnostic accuracy and detected recurrent disease in 37 of 76
patients (49%) (Po0.05).
Of the 12 patients with rise in tumour markers and normal CTs,
CEA was elevated in eight and CA 19-9 in nine (both in 5). Of the
six where tumour markers and imaging both suggested a
recurrence five patients had an elevated CEA and five elevated
CA 19-9. In the 12 patients with elevated tumour markers with
normal CT, there was a median lag period of 3 months (range 1–21
months) before recurrence was detected on further imaging.
Nineteen patients had recurrent metastases in the liver alone.
Eight (42%) presented within 6 months of surgery. None of these
had resectable disease on repeat staging. Eleven (58%) presented
after 6 months, of whom five (45%) were resectable. Four of these
patients underwent a further liver resection. One patient refused
further surgery. One of the patients undergoing a repeat hepatic
resection developed a further recurrence at 18 months. The other
three patients have remained well and disease-free (median follow-
up of 30 months (range 12–54 months)). Of the 53 patients who
had received chemotherapy before the initial liver resection, 26
(49%) developed recurrent disease (18 Dukes’ B and 8 Dukes’ C).
Of the 23 patients who did not receive initial chemotherapy, 11
(49%) developed recurrence.
The cost of the current protocol that identified five out of 76
patients who could have been potentially cured by repeat liver
resection was d310080.00 over a 2-year period (cost per CT
scan¼d500.00; cost per CEA and CA19-9 estimation at d5.00 per
test; total of (76 8) 608 scans and blood tests). Therefore, the cost
per patient potentially cured per year was d31000. The cost of
following up an individual patient by this protocol was d2040.00
per year.
DISCUSSION
Intensive follow-up programmes to screen for recurrent cancer
should be designed to detect disease in a selected population
where a therapeutic intervention altering ultimate prognosis and
survival can be offered. Where this is not possible, these tests
unnecessarily enhance patient anxiety and may reduce their
overall quality of life. A selective approach is often required to
justify the costs of screening, which has an unacceptable cost–
benefit ratio when applied universally (Beard et al, 2000;
Gazelle et al, 2003).
The surveillance programme used in this study of patients who
had undergone resection of colorectal liver metastases detected
recurrent disease in 49% of patients. Of these recurrences, 51%
Table 2 Initial liver resections performed
Dukes’
stage R Hemihepatectomy
Extended R
Hemihepatectomy L Hemihepatectomy
Extended L
Hemihepatectomy
Segment/wedge
resection
Ext. hemihepatectomy+
wedge
A 1
B1 0 8 1 1 9 3
C5 4 3 21 8 2
Total 15 12 4 2 38 5
L, left, R, right.
Table 3 Sites of recurrence during follow-up of 76 patients with
resected colorectal liver metastases
Recurrence sites Total no.
Recurrence
o6/12
Recurrence
46/12
Liver only 19 8 11
Liver+lungs 13 5 8
Liver+lymph nodes 3 1 2
Other 2 1 1
Recurrence o6/12, recurrence diagnosed within 6 months of liver resection;
recurrence 46/12, recurrence diagnosed beyond 6 months of liver resection.
Intensive follow-up after liver resection
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swere in the liver alone, 43% liver and extrahepatic and 6%
extrahepatic alone. This incidence and pattern of recurrence is
similar to data previously published (Sugihara et al, 1993) and
confirms that the majority of patients developing recurrence
develop liver- alone disease, which could potentially be amenable
to further liver surgery (Topal et al, 2003). Where surgery is not
possible, alternate therapies like radiofrequency ablation may
provide local tumour control (Gillams and Lees, 2005).
None of the patients with recurrent liver metastases detected
within 6 months of their liver resection had resectable disease.
These early recurrences may represent microscopic metastatic
disease or occult metastases present at the time of liver resection
that only becomes apparent under the trophic effects of liver
regeneration. Local recurrence owing to incomplete resection of
the liver metastases is unlikely as patients with histologically
involved liver resection margins were not included in this follow-
up study. The ability to detect occult disease is limited by the
technical resolution of currently available imaging equipment.
Intra-operative ultrasound is the most sensitive technique and all
these patients had had an intra-operative ultrasound at the time of
first liver resection (Machi et al, 1987; Agrawal et al, 2006). As
none of these patients proved to be amenable to further liver
resection they will represent a poor prognosis group in whom
surveillance is less likely to be beneficial.
Of the patients who developed liver metastases after 6 months, a
further curative resection was possible in 45%. The reported 5-year
survival in patients undergoing repeat resections of their liver
metastases is in the region of 35–40% (Yamamoto et al, 1999a;
Beard et al, 2000; Muratore et al, 2001; Suzuki et al, 2001; Yamada
et al, 2001a; Gazelle et al, 2003) and therefore a follow-up aimed at
detecting these resectable recurrences is useful and should be
instigated at 6 months.
On follow-up the incidence of recurrent liver metastases
following liver resection in patients whose colorectal cancer was
Dukes’ B and C was similar (49 vs 50%). Recurrence after 6 months
was higher in patients with Dukes’ B cancer, although the
difference was not statistically significant. A predominance of late
recurrences in the less-advanced Dukes stage may have been
anticipated and the lack of significance may be owing to the small
number of patients in the study and requires to be validated in a
larger series. The Dukes stage of the colon cancer is a factor
influencing outcome in multivariate analysis of first liver resection
(Fong et al, 1999). In this study, the Dukes stage did not influence
the recurrence rate following liver resection. No association was
observed between the number of tumour nodules and frequency of
recurrence. Although the presence of more than a single metastasis
has been reported to be associated with a poorer overall outcome
with liver resection (Fong et al, 1999; Muratore et al, 2001; Yamada
et al, 2001b), whether it is the absolute number of metastases or
the total volume of metastatic disease that affects outcome is not
known (Muratore et al, 2001). In the current study, the outcome of
solitary and multiple liver metastases in terms of disease
recurrence was similar, supporting the role of liver resection in
patients with multiple liver metastases. Similar results have been
reported in the literature (Ambiru et al, 1999; Fong et al, 1999;
Yamamoto et al, 1999b).
The incidence of nonsecretory colorectal cancers is in the order
of 20% (Duffy, 2001; Carpelan-Holmstrom et al, 2002). In this
study, 17 of 76 (22%) patients with colorectal liver metastases had
normal tumour markers. The mechanism underlying expression of
CEA in patients with liver metastases whose primary cancers did
not express CEA are unclear. Possible explanations include the
degree of differentiation of the primary tumour, effects of
transforming growth factora, tumour/host lymphocyte interactions
Table 4 Patterns of recurrence
Dukes’ stage of primary Number of patients No recurrence Recurrence o6/12 Recurrence 46/12
A1 1 0 0
B4 1 2 1 6 1 4
C3 4 1 7 9 8
Number of metastases No. of patients No recurrence Recurrence o6/12 Recurrence 46/12
H1 (o2) 30 15 6 9
H2 (2–5) 44 23 9 12
H3 (45) 2 1 0 1
Liver resection No. of patients No recurrence Recurrence o6/12 Recurrence 46/12
R hemihepatectomy 15 8 4 3
Ext. R hemihepatectomy 12 6 4 2
L hemihepatectomy 4 2 0 2
Ext. L hemihepatectomy 2 1 0 1
Segmental or wedge resection 38 20 7 11
Ext. hemihepatectomy+wedge 5 2 0 3
Recurrence o6/12, recurrence diagnosed within 6 months of liver resection; recurrence 46/12, recurrence diagnosed beyond 6 months of liver resection; H1, solitary liver
metastasis; H2, 2–5 liver metastases; H3, 45 liver metastases.
Table 5 Results of surveillance
Surveillance result Recurrence o6/12 Recurrence 46/12
CEA/CA 19-9 elevated
before liver resection
CEA/CA 19-9 raised before CT evidence 5 7 5 (2,3)
CT evidence before raised CEA/CA 19-9 8 11 12 (6,6)
CT and CEA/CA 19-9 correlate evidence 2 4 3 (2,1)
CEA, carcinoembryonic antigen 45ngml
 1; CA 19-9, carbohydrate antigen 19-9 437Uml
 1; CT, computed tomography; recurrence o6/12, recurrence diagnosed within 6
months of liver resection; recurrence 46/12, recurrence diagnosed beyond 6 months of liver resection.
Intensive follow-up after liver resection
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scausing hepatocyte apoptosis or a loss of hepatic first-pass effect
(Duffy, 2001). An important finding in this study is that 60% of the
patients who had normal tumour markers before resection of their
liver metastases had elevated tumour markers with recurrence.
This would suggest that serial tumour marker assessments should
be performed in all patients during follow-up irrespective of the
levels before resection of the metastases. While the role of CEA in
screening following resection of colorectal liver metastases is well-
documented (Hohenberger et al, 1994; McCall et al, 1994;
Paganuzzi et al, 1994; Lucha et al, 1997; Novell et al, 1997;
Hocking and Morris, 1998; Wichmann et al, 2000; Ishizuka et al,
2001), there is less published evidence on the use of CA 19-9
(Ishizuka et al, 2001; Carpelan-Holmstrom et al, 2002). In the
present study, CEA and CA19-9 were found to be of similar value
and complementary in the detection of recurrence following liver
resection.
In this study, a protocol of using both tumour markers and CT
in the postoperative period improved the detection of recurrent
disease. The likelihood of repeat hepatic resection for patients with
isolated liver recurrences is less with early recurrences (in this
study none) as compared to delayed isolated liver recurrence.
This finding needs to be validated in larger studies. Even if
early detection does not allow potentially curative resection of
recurrent liver metastases, there may be significant clinical
benefit to the earlier commencement of systemic chemotherapy
or the use of radiofrequency ablation (Elias et al, 2004; Gillams and
Lees, 2005). The timing of recurrence and its implications for
therapy and patient outcome is vital to the design of follow-up
protocols.
Cost–benefit analysis must be considered carefully when
designing a follow-up screening protocol. This study would
suggest that a similar detection of resectable disease could be
achieved at lower cost by a protocol of serial tumour marker
estimations and CT scans starting at 6 months after initial surgery.
This approach, however, assumes that early recurrences (within 6
months) are never resectable and also disregards the possible
benefit from the early commencement of chemotherapy or
radiofrequency ablation in patients with unresectable disease.
The issue of cost–benefit analysis in this context requires further
analysis. However, this altered protocol would significantly
decrease the costs from d31008 to d22542 per patient potentially
cured per year (Po0.001). Similar costs have been reported with
an aggressive approach to colorectal liver metastases that have
resulted in an increase in quality of life adjusted years (Gazelle
et al, 2003).
The design of a follow-up protocol depends on the pattern of
recurrent disease. In the present study, recurrence was found in
47% of patients within 2 years of liver resection for colorectal
metastases. The initial 2-year period is recognised as being the
main-risk period for recurrence (Scheele et al, 1995). Disease
recurrence occurs in the majority of patients in the liver alone and
in a proportion of these a further curative resection may be
possible. Our data would suggest that tumours recurring early
following liver resection are less likely to be amenable to re-
resection. However, this observation was based on a small number
of patients and needs to be validated by data from other centres.
The pattern of recurrence would support a surveillance pro-
gramme being more intense in the first 2 years, but the frequency
of imaging within this time frame requires further investigation.
In conclusion, this study has demonstrated that both CEA and
CA19-9 are useful in the detection of recurrent disease following
potentially curative resection of liver metastases and these are
complementary to spiral CT. Early recurrences were not amenable
to further surgery, but those detected after 6 months were often
resectable. The tumour marker/CT follow-up protocol costs were
d31K per patient per year.
REFERENCES
Agrawal N, Fowler AL, Thomas MG (2006) The routine use of intra-
operative ultrasound in patients with colorectal cancer improves the
detection of hepatic metastases. Colorectal Dis 8: 192–194
Ambiru S, Miyazaki M, Isono T, Ito H, Nakagawa K, Shimizu H, Kusashio
K, Furuya S, Nakajima N (1999) Hepatic resection for colorectal
metastases: analysis of prognostic factors. Dis Colon Rectum 42:
632–639
Ballantyne GH, Quin J (1993) Surgical treatment of liver metastases in
patients with colorectal cancer. Cancer 71: 4252–4266
Baulieu F, Bourlier P, Scotto B, Mor C, Eder V, Picon L, De Calan L, Dorval
E, Pottier JM, Baulieu JL (2001) The value of immunoscintigraphy in the
detection of recurrent colorectal cancer. Nucl Med Commun 22: 1295–
1304
Beard SM, Holmes M, Price C, Majeed AW (2000) Hepatic resection for
colorectal liver metastases: a cost-effectiveness analysis. Ann Surg 232:
763–776
Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE (1981) Natural history of
patients with untreated liver metastases from colorectal cancer. Am J
Surg 141: 586–589
Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF,
Davidson BR (2004) Prospective study of contrast-enhanced computed
tomography, computed tomography during arterioportography, and
magnetic resonance imaging for staging colorectal liver metastases for
liver resection. Br J Surg 91: 1361–1369
Biggs CG, Ballantyne GH (1994) Postoperative follow-up for colorectal
cancer: sensitivity vs. cost effectiveness. In Current Opinion in General
Surgery Current Science, Daly JM. (ed) 2nd Edition, pp 94–102.
Philadelphia
Bolton JS, Fuhrman GM (2000) Survival after resection of multiple bilobar
hepatic metastases from colorectal carcinoma. Ann Surg 231: 743–751
Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Haglund C
(2002) CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in
gastrointestinal cancers. Anticancer Res 22: 2311–2316
Daly JM, Bertagnolli M, De Cosse JJ, Morton DJ (1989) Oncology. In
Principles of Surgery, Schwartz SI, Shires GT, Spencer FC (eds) pp 297–
360. New York: McGraw Hill Book Co
Duffy MJ (2001) Carcinoembryonic antigen as a marker for colorectal
cancer: is it clinically useful? Clin Chem 47: 624–630
Elias D, Baton O, Sideris L, Matsuhisa T, Pocard M, Lasser P (2004) Local
recurrences after intraoperative radiofrequency ablation of liver
metastases: a comparative study with anatomic and wedge resections.
Ann Surg Oncol 11: 500–505
Fantini GA, DeCosse JJ (1990) Surveillance strategies after resection of
carcinoma of the colon and rectum. Surg Gynecol Obstet 171: 267–273
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical
score for predicting recurrence after hepatic resection for metastatic
colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:
309–318
Fujimoto S, Miyazaki M, Kitsukawa Y, Higuchi M, Okui K (1985) Long-
term survivors of colorectal cancer with unresectable hepatic metastases.
Dis Colon Rectum 28: 588–591
Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M,
Lester JS, Tanabe KK, Weinstein MC (2003) Cost-effectiveness of hepatic
metastasectomy in patients with metastatic colorectal carcinoma: a state-
transition Monte Carlo decision analysis. Ann Surg 237: 544–555
Giacchi R, Sebastiani M, Lungarotti F (1988) Natural history of
synchronous hepatic metastases from a non-treated colorectal cancer.
J Chir (Paris) 125: 419–423
Gillams AR, Lees WR (2005) Radiofrequency ablation of colorectal liver
metastases. Abdom Imag 30: 419–426
Glover C, Douse P, Kane P, Karani J, Meire H, Mohammadtaghi S, Allen-
Mersh TG (2002) Accuracy of investigations for asymptomatic colorectal
liver metastases. Dis Colon Rectum 45: 476–484
Hocking RA, Morris DL (1998) Patterns of serum CEA fall after hepatic
arterial chemotherapy as sole therapy and combined with cryotherapy
for colorectal metastases. Aust N Z J Surg 68: 722–724
Intensive follow-up after liver resection
S Bhattacharjya et al
25
British Journal of Cancer (2006) 95(1), 21–26 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sHohenberger P, Schlag PM, Gerneth T, Herfarth C (1994) Pre- and post-
operative carcinoembryonic antigen determinations in hepatic resection
for colorectal metastases. Predictive value and implications for adjuvant
treatment based on multivariate analysis. Ann Surg 219: 135–143
Ishizuka D, Shirai Y, Sakai Y, Hatakeyama K (2001) Colorectal carcinoma
liver metastases: clinical significance of preoperative measurement of
serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels.
Int J Colorectal Dis 16: 32–37
Leow CK, Lau WY, Li AK (1997) Surgical resection of colorectal hepatic
metastases. Hong Kong Med J 3: 50–56
Longo WE, Johnson FE (2002) The preoperative assessment and post-
operative surveillance of patients with colon and rectal cancer. Surg Clin
NA m82: 1091–1108
Lucha Jr PA, Rosen L, Olenwine JA, Reed III JF, Riether RD, Stasik Jr JJ,
Khubchandani IT (1997) Value of carcinoembryonic antigen monitoring
in curative surgery for recurrent colorectal carcinoma. Dis Colon Rectum
40: 145–149
Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O (2001) Combined
colon and hepatic resection for synchronous colorectal liver metastases.
J Surg Oncol 78: 17–21
Machi J, Isomoto H, Yamashita Y, Kurohiji T, Shirouzu K, Kakegawa T
(1987) Intraoperative ultrasonography in screening for liver metastases
from colorectal cancer: comparative accuracy with traditional proce-
dures. Surgery 101: 678–684
Malafosse R, Penna C, Sa CA, Nordlinger B (2001) Surgical management of
hepatic metastases from colorectal malignancies. Ann Oncol 12: 887–894
McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, Toouli J
(1994) The value of serum carcinoembryonic antigen in predicting
recurrent disease following curative resection of colorectal cancer. Dis
Colon Rectum 37: 875–881
McCormick D, Kibbe PJ, Morgan SW (2002) Colon cancer: prevention,
diagnosis, treatment. Gastroenterol Nurs 25: 204–211
Muratore A, Polastri R, Bouzari H, Vergara V, Ferrero A, Capussotti L
(2001) Repeat hepatectomy for colorectal liver metastases: a worthwhile
operation? J Surg Oncol 76: 127–132
Norum J, Gerner T, Bergan A, Lange O (1997) Follow up after potential
curative surgery of colorectal cancer. Guidelines from the Norwegian
Gastrointestinal Cancer Group. Tidsskr Nor Laegeforen 117: 2965–2968
Novell F, Trias M, Molina R, Filella X (1997) Detection of occult liver
metastases in colorectal cancer by measurement of biliary carcinoem-
bryonic antigen. Anticancer Res 17: 2743–2746
Paganuzzi M, Onetto M, de Paoli M, Castagnola M, de Salvo L, Civalleri D,
Grossi CE (1994) Carcinoembryonic antigen (CEA) in serum and bile of
colorectal cancer patients with or without detectable liver metastases.
Anticancer Res 14: 1409–1412
Rudy DR, Zdon MJ (2000) Update on colorectal cancer. Am Fam Physician
61: 1759–1770
Ruers T, Bleichrodt RP (2002) Treatment of liver metastases, an update on
the possibilities and results. Eur J Cancer 38: 1023–1033
Ruiz E, Celis J, Berrospi F, Payet E (2000) Surgical treatment of the liver
metastases from colorectal cancer. Rev Gastroenterol Peru 20: 376–383
Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of
colorectal liver metastases. World J Surg 19: 59–71
Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from
colorectal carcinoma: impact of surgical resection on the natural history.
Br J Surg 77: 1241–1246
Sugihara K, Hojo K, Moriya Y, Yamasaki S, Kosuge T, Takayama T (1993)
Pattern of recurrence after hepatic resection for colorectal metastases. Br
J Surg 80: 1032–1035
Suzuki S, Sakaguchi T, Yokoi Y, Kurachi K, Okamoto K, Okumura T,
Tsuchiya Y, Nakamura T, Konno H, Baba S, Nakamura S (2001) Impact
of repeat hepatectomy on recurrent colorectal liver metastases. Surgery
129: 421–428
Tartter PI, Slater G, Gelernt I, Aufses Jr AH (1981) Screening for liver
metastases from colorectal cancer with carcinoembryonic antigen and
alkaline phosphatase. Ann Surg 193: 357–360
Topal B, Kaufman L, Aerts R, Penninckx F (2003) Patterns of failure
following curative resection of colorectal liver metastases. Eur J Surg
Oncol 29: 248–253
Tuttle TM, Curley SA, Roh MS (1997) Repeat hepatic resection as effective
treatment of recurrent colorectal liver metastases. Ann Surg Oncol 4:
125–130
Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y (2000)
Survival after resection of multiple hepatic colorectal metastases. Ann
Surg Oncol 7: 643–650
Wichmann MW, Lau-Werner U, Muller C, Hornung HM, Stieber P,
Schildberg FW (2000) Carcinoembryonic antigen for the detection of
recurrent disease following curative resection of colorectal cancer.
Anticancer Res 20: 4953–4955
Yamada H, Katoh H, Kondo S, Okushiba S, Morikawa T (2001a) Repeat
hepatectomy for recurrent hepatic metastases from colorectal cancer.
Hepatogastroenterology 48: 828–830
Yamada H, Kondo S, Okushiba S, Morikawa T, Katoh H (2001b) Analysis of
predictive factors for recurrence after hepatectomy for colorectal liver
metastases. World J Surg 25: 1129–1133
Yamaguchi J, Yamamoto M, Komuta K, Fujioka H, Furui JI, Kanematsu T
(2000) Hepatic resections for bilobar liver metastases from colorectal
cancer. J Hepatobiliary Pancreat Surg 7: 404–409
Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Moriya Y, Sugihara K
(1999a) Repeat liver resection for recurrent colorectal liver metastases.
Am J Surg 178: 275–281
Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H
(1999b) Factors influencing survival of patients undergoing hepatectomy
for colorectal metastases. Br J Surg 86: 332–337
Intensive follow-up after liver resection
S Bhattacharjya et al
26
British Journal of Cancer (2006) 95(1), 21–26 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s